Drug Profile
Research programme: gene therapies - Krystal Biotech
Alternative Names: Filaggrin gene therapy - Krystal Biotech; KB106Latest Information Update: 03 Feb 2023
Price :
$50
*
At a glance
- Originator Krystal Biotech
- Class Gene therapies; Skin disorder therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Atopic dermatitis; Skin aging; Wounds
Most Recent Events
- 03 Feb 2023 Discontinued - Preclinical for Skin aging in USA (Parenteral)
- 03 Feb 2023 Discontinued for Atopic dermatitis in USA (Parenteral)
- 03 Feb 2023 Discontinued for Wounds in USA (Parenteral)